Company intelligence / Profile preview

Universal Agency

Ownership: Private
Development stage: Other

Overview

Universal DX’s lead program is Signal-C®, a blood-based screening test for early detection of colorectal cancer. In large multi-cohort studies, Signal-C demonstrated 93% sensitivity for colorectal cancer and 54% sensitivity for advanced adenoma at 92% specificity. The company has initiated an FDA validation trial in the US with Quest Diagnostics as its partner. Data have been presented at major conferences including ASCO GI and Digestive Disease Week. The technology is also being explored for other high-burden cancers such as lung, pancreatic, liver, and esophageal cancers.

Therapeutic areas: Oncology
Modalities: Diagnostic test (cfDNA-based)Next-generation sequencing (NGS)Bioinformatics/AI-enabled diagnostics
Industry: Molecular Diagnostics

Partnerships

Quest Diagnostics [US commercialization/distribution partner for Signal-C]

Beyond the preview

Go deeper on Universal Agency.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universal Agency.

Explore the full profile